Hoth Therapeutics
Hoth Therapeutics (HOTH) announced that its product, HT-003, has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of toll-like receptor 2 (TLR2
This content is for paid subscribers.
Trick or Trade
July 14, 2021
